Powered by
Read the full press release here. With promising results on its first rheumatological protein therapies, Dianomi is strategically expanding upon its core technology to deliver next-generation nucleic acid therapies MADISON, Wis., Feb. 11, 2020 /PRNewswire/ — Dianomi Therapeutics Inc. today announced that it…
Thursday, July 18, Morgridge Institute for Research wrapped up their third week of summer camp programming offered at the Wisconsin Institute of Discovery building. The Morgridge Rural Summer Science Camps focused on giving rural high school students and teachers a…
There are vast numbers of organizations and opportunities available in Wisconsin’s Biohealth Industry. As part of BioForward Wisconsin’s Talent Initiative, we are making it easy for talent to see that Wisconsin is the place to be for a career in…
Aldevron announced today its new fermentation capacity of 1,000 liters and plans to significantly increase the Company’s manufacturing footprint in Madison, WI. The large-scale fermentation equipment is already installed and will be coming on-line in Q4 2019. The new fermentation…
Madison biopharmaceutical company Dianomi Therapeutics has raised $3 million in funding following a partnership with publicly traded drug company Ligand Pharmaceuticals. Dianomi announced Tuesday that Ligand invested $3 million in the startup in exchange for a royalty of two or three percent based…